Nucleus Network
Melbourne, Victoria, 3004, Australia
Completed
NCT Number: NCT03551769
Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production
This is a Phase I, single center, open label, fixed-order, crossover, food-effect, pharmacokinetic (PK) study recruiting healthy, adult, male subjects.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy adult male, ages 18 - 55
- Able to consume a regular diet and one high fat meal; no specific dietary requirements
- Cohort 2 (Asian subject population) restricted to being of Japanese or Chinese heritage
Exclusion criteria
- Presence of any illness or condition that, in the opinion of the investigator might confound the study results or poses risk to the subject
- Has been on a ketogenic diet as supported by review of a food diary
- Has positive Urine Drug Screen or alcohol results at Screening
Treatment and study plan
Tricaprilin
DrugTricaprilin formulated as AC-SD-01
Standard meal
Otherstandard meal
High-fat Meal
Otherhigh-fat meal
Overnight fast
Otherfasting for at least 9 hours
Primary outcomes
-
Total ketones
Time frame: 1 day
Area Under the Curve (AUC) AUC 0-last
-
Total ketones
Time frame: 1 day
AUC 0 - 4
-
Total ketones
Time frame: 1 day
AUC 0 - 6
-
Total ketones
Time frame: 1 day
AUC 0-8
-
Total ketones
Time frame: 1 day
Maximum Plasma Concentration (Cmax)
-
B-hydrodxybutyrate
Time frame: 1 day
AUC 0-last
-
B-hydroxybutyrate
Time frame: 1 day
AUC 0-4
-
B-hydroxybutyrate
Time frame: 1 day
AUC 0-6
-
B-hydroxybutyrate
Time frame: 1 day
AUC 0-8
-
B-hydroxybutyrate
Time frame: 1 day
Cmax
-
Acetoacetate
Time frame: 1 day
AUC 0-last
-
Acetoacetate
Time frame: 1 day
AUC 0-4
-
Acetoacetate
Time frame: 1 day
AUC 0-6
-
Acetoacetate
Time frame: 1 day
AUC 0-8
-
Acetoacetate
Time frame: 1 day
Cmax
Secondary outcomes
-
tricaprilin
Time frame: 1 day
AUC 0 - last
-
tricaprilin
Time frame: 1 day
AUC 0 - 4
-
tricaprilin
Time frame: 1 day
AUC 0 - 6
-
tricaprilin
Time frame: 1 day
AUC 0 - 8
-
tricaprilin
Time frame: 1 day
Time to maximum concentration (Tmax)
-
tricaprilin
Time frame: 1 day
Cmax
-
octanoic acid
Time frame: 1 day
AUC 0 - last
-
octanoic acid
Time frame: 1 day
AUC 0 - 4
-
octanoic acid
Time frame: 1 day
AUC 0 - 6
-
octanoic acid
Time frame: 1 day
AUC 0 - 8
-
octanoic acid
Time frame: 1 day
Tmax
-
octanoic acid
Time frame: 1 day
Cmax
-
Computerized Cognitive Battery - Attention
Time frame: 1 day
Rapid Visual Information Processing Test
-
Computerized Cognitive Battery - Episodic Memory
Time frame: 1 day
Paired Associates Learning Test
-
Computerized Cognitive Battery - Working Memory
Time frame: 1 day
Spatial Working Memory Test
-
Computerized Cognitive Battery - Psychomotor Function
Time frame: 1 day
Reaction Time Test
Sponsors and collaborators
Lead sponsor
Cerecin
Industry
Registry information
Official study title
A Phase I, Open-label, Fixed-order, Single-dose, 2-Part, Crossover Study to Evaluate the Pharmacokinetics of a Formulation of Tricaprilin (AC-SD-01) Including the Effect of Food on Ketone Body Production in Caucasians and Asians
Important dates
- Study start
- 2018
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Jun 11, 2018
- Registry last updated
- May 29, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
NCT04865172
Alzheimer Disease, Brain Diseases
Paris, France
View Trial Details
Completed
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial Details
Completed
Impact of COVID-19 Vaccines on Cerebrovascular Health
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details
Completed
Community-based Brain Health Program to Address Dementia Risk
NCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial Details